Abstract: Functional imaging using 18fluorodeoxyglycose (18FFDG) positron emission tomography combined with computed tomography (PET/CT) has become a major imaging modality in Hodgkin lymphoma with a definite role in the staging of Hodgkin lymphoma. It is a predictive treatment tool that is constantly evolving through the use of responseadaptive therapies. A large number of clinical studies have shown that 18FFDG PET/CT has a very high prognostic value for HL,  which can improve the accuracy of staging and identify residual tumors and fibrotic tissues. The responseadaptive treatment in HL can reduce the toxicity to lowrisk patients by reducing the dose, and also improve the prognosis by increasing the intensity of treatment for highrisk patients. This review describes the application of 18FFDG PET/CT to the diagnosis, staging and end of treatment in HL, and explores the new functional prognostic factors for total metabolic tumor volume.

Key words: hodgkin disease；fluorodeoxyglucose f18；positronemission tomography and computed tomography；tumor markers, , biological